Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19

数据表明，预防由呼吸道合胞病毒、人类偏肺病毒和新型冠状病毒引起的严重呼吸道感染的重要性

AstraZeneca will share new data across its Vaccines & Immune Therapies portfolio at the 13th annual IDWeek in Los Angeles, California, from 16-19 October 2024. The Company will highlight progress in advancing novel immunisations against infectious diseases of high unmet need and share real-world evidence showing the burden of respiratory viral infections and the continued need for protection..

阿斯利康将于2024年10月16日至19日在加利福尼亚州洛杉矶举行的第13届年度IDWeek上分享其疫苗和免疫疗法组合的新数据。该公司将重点介绍在推进针对高度未满足需求的传染病的新型免疫接种方面取得的进展，并分享显示呼吸道病毒感染负担和持续保护需求的现实证据。。

Iskra Reic, Executive Vice President of Vaccines & Immune Therapies, AstraZeneca, said: “The data being presented at IDWeek demonstrate our commitment to addressing the impact of infectious diseases, notably our progress in developing our vaccine and antibody candidates against viral and bacterial pathogens, including IVX-A12, the first potential combination RSV/hMPV vaccine, and AZD5148 against C.

阿斯利康疫苗与免疫疗法执行副总裁Iskra Reic说：“IDWeek上提供的数据表明我们致力于应对传染病的影响，特别是我们在开发针对病毒和细菌病原体的疫苗和抗体候选物方面取得的进展，包括第一种潜在的RSV/hMPV联合疫苗IVX-A12和针对C的AZD5148。

diff infections. The advancement of IVX-A12 builds on our scientific leadership in RSV, with data being presented on Beyfortus demonstrating how, in its first season, it has delivered significant real-world impact in protecting a broad infant population against the disease, with millions more children set to benefit this season.”.

差异感染。IVX-A12的进步建立在我们在RSV方面的科学领导地位的基础上，Beyfortus上提供的数据表明，在第一季中，它在保护广大婴儿免受疾病侵害方面产生了重大的现实影响，数百万儿童将受益于本季。”。

Data in RSV, combination vaccines, C. diff and influenza

RSV，联合疫苗，C.diff和流感的数据

Data will be presented on Beyfortus (nirsevimab), AstraZeneca’s long-acting antibody for the prevention of RSV disease, showing that Beyfortus does not interfere with RSV detection by rapid antigen tests enabling accurate diagnosis to support clinical management.10 Additional data, presented by our partner Sanofi, confirm the significant real-world effectiveness of Beyfortus in reducing RSV disease and hospitalisations in infants.

。

These data build on recent evidence, including from the US Advisory Committee on Immunisation Practices, demonstrating Beyfortus was associated with a 90% reduction in RSV-associated hospitalisations in its first season..

这些数据基于最近的证据，包括来自美国免疫实践咨询委员会的证据，证明Beyfortus在第一季度与RSV相关的住院率降低了90%。。

Interim Phase II data on IVX-A12, an investigational combination virus-like particle vaccine, will be presented, demonstrating that IVX-A12 was well-tolerated and immunogenic against both RSV and hMPV in older adults 60 to 85 years of age.6,7

将提供关于IVX-A12（一种研究性组合病毒样颗粒疫苗）的II期中期数据，证明IVX-A12在60至85岁的老年人中对RSV和hMPV具有良好的耐受性和免疫原性[6,7]

Pre-clinical data will be shared showing that AZD5148, an anti-toxin B neutralizing monoclonal antibody now in Phase I trials, may provide protection against Clostridioides difficile (C. diff) infection, a condition that can cause life-threatening diarrhea and intestinal inflammation.9

临床前数据将共享，显示AZD5148是一种抗毒素B中和单克隆抗体，目前正在进行I期试验，可以提供针对艰难梭菌（C.diff）感染的保护，这种情况可能导致危及生命的腹泻和肠道炎症

Additionally, AstraZeneca is presenting vaccine effectiveness data for FluMist (live attenuated influenza vaccine), recently approved in the US as the only vaccine for self- or caregiver administration for the prevention of influenza.8

此外，阿斯利康正在提供FluMist（减毒活流感疫苗）的疫苗有效性数据，该疫苗最近在美国被批准为唯一用于自我或护理人员预防流感的疫苗

Real-world evidence shows the need for protection against respiratory viral infections

现实世界的证据表明需要防止呼吸道病毒感染

Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are in the same family of respiratory viruses and can cause serious respiratory infections, especially in children, older adults and those with co-morbid conditions.1 AstraZeneca will present data highlighting the seasonal patterns of hMPV and RSV, reflecting a return to pre-pandemic seasonality.

呼吸道合胞病毒（RSV）和人类偏肺病毒（hMPV）属于同一呼吸道病毒家族，可引起严重的呼吸道感染，尤其是儿童，老年人和合并症患者。阿斯利康将提供数据，突出hMPV和RSV的季节性模式，反映出大流行前季节性的恢复。

Overlapping seasonal patterns of hMPV and RSV were seen in most countries, underscoring the importance of continued surveillance during the coming season and the potential benefit of a combination vaccine that offers protection against both viruses.2.

在大多数国家，hMPV和RSV的季节性模式重叠，强调了在未来季节继续监测的重要性以及提供两种病毒保护的联合疫苗的潜在益处。

Additional findings analysed hMPV outcomes in nursing homes, indicating that in high-risk older adults, hMPV outcomes of hospitalisation and death were comparable with influenza.3 These analyses highlight the risk that hMPV can present to high-risk older adults living in nursing homes and the need for advancements in testing and prevention.3.

另外的研究结果分析了疗养院的hMPV结果，表明在高危老年人中，住院和死亡的hMPV结果与流感相当[3]。这些分析强调了hMPV可能给居住在疗养院的高危老年人带来的风险以及需要在检测和预防方面取得进展。

Updated data from INFORM, a retrospective health database observational study in England, highlight the continued burden of COVID-19 on immunocompromised patients.4,5 Findings show the continued increased risk of COVID-19 hospitalisation and death in immunocompromised patients despite receiving ≥4 vaccine doses, as well as consistently showing higher COVID-19 mortality among hospitalised immunocompromised individuals compared to non-immunocompromised individuals.4,5.

英国回顾性健康数据库观察性研究INFORM的最新数据突出了新型冠状病毒肺炎对免疫功能低下患者的持续负担[4,5]。研究结果显示，尽管接受≥4次疫苗，免疫功能低下患者的新型冠状病毒肺炎住院和死亡风险持续增加剂量，并且与非免疫功能低下患者相比，住院免疫功能低下患者的新型冠状病毒肺炎死亡率始终较高[4,5]。

Key AstraZeneca presentations during IDWeek 2024

2024年IDWeek期间阿斯利康的主要演讲

Abstract Title

摘要标题

Presentation Details

演示文稿详细信息

IVX-A12

IVX-A12

Safety and immunogenicity of a Respiratory Syncytial Virus and human Metapneumovirus virus-like particle protein subunit combination vaccine in 60–85-year-old adults: interim results from a Phase 2a clinical trial

呼吸道合胞病毒和人类偏肺病毒样颗粒蛋白亚单位联合疫苗在60-85岁成年人中的安全性和免疫原性：2a期临床试验的中期结果

Poster Presentation

海报展示

Session Title: New Vaccines

课程名称：新疫苗

Date: Thursday, October 17, 2024

日期：2024年10月17日，星期四

Time: 12:15 PM – 1:30 PM PT

时间：下午12:15–1:30 PT

Location: Halls J & K

地点：J&K大厅

Human Metapneumovirus (hMPV) Real-World Evidence

人类偏肺病毒（hMPV）的真实世界证据

Global surveillance of human Metapneumovirus (hMPV) and Respiratory Syncytial Virus (RSV) epidemiology since 2022

自2022年以来全球人类偏肺病毒（hMPV）和呼吸道合胞病毒（RSV）流行病学监测

Poster Presentation

海报展示

Session Title: Virology: Epidemiology of Viral Infections

课程名称：病毒学：病毒感染的流行病学

Date: Saturday, October 19, 2024

日期：2024年10月19日，星期六

Time: 12:15 PM – 1:30 PM PT

时间：下午12:15–1:30 PT

Location: Halls J & K

地点：J&K大厅

Outcomes of human Metapneumovirus in nursing home residents: a matched analysis

人类偏肺病毒在疗养院居民中的结果：匹配分析

Poster Presentation

海报展示

Session Title: HAIs: Non-Acute Care

会议标题：Hais：非急性护理

Date: Thursday, October 17, 2024

日期：2024年10月17日，星期四

Time: 12:15 PM – 1:30 PM PT

时间：下午12:15–1:30 PT

Location: Halls J & K

地点：J&K大厅

COVID-19 Real World Evidence

新型冠状病毒肺炎的真实证据

Individuals on immunosuppressive or immunomodulatory therapies remain at increased risk of COVID-19 hospitalization, despite vaccination: findings from INFORM, a retrospective health database study in England

尽管接种了疫苗，但接受免疫抑制或免疫调节疗法的个体仍有增加的新型冠状病毒住院风险：英国回顾性健康数据库研究INFORM的发现

Poster Presentation

海报展示

Session Title: Covid-19: Special Populations

会议标题：新型冠状病毒肺炎：特殊人群

Date: Saturday, October 19, 2024

日期：2024年10月19日，星期六

Time: 12:15 PM – 1:30 PM PT

时间：下午12:15–1:30 PT

Location: Halls J & K

地点：J&K大厅

COVID-19 mortality among immunocompromised individuals is consistently high compared with non-immunocompromised individuals: results of the INFORM study, England

英国INFORM研究的结果表明，与非免疫功能低下的个体相比，免疫功能低下的个体中的新型冠状病毒肺炎死亡率一直很高

Poster Presentation

海报展示

Session Title: Covid-19: Special Populations

会议标题：新型冠状病毒肺炎：特殊人群

Date: Saturday, October 19, 2024

日期：2024年10月19日，星期六

Time: 12:15 PM – 1:30 PM PT

时间：下午12:15–1:30 PT

Location: Halls J & K

地点：J&K大厅

Beyfortus (nirsevimab)

Beyfortus（尼舍维马）

Nirsevimab in patient samples does not interfere with Respiratory Syncytial Virus (RSV) detection by commercially available rapid antigen tests

患者样本中的尼塞维单抗不干扰市售快速抗原检测呼吸道合胞病毒（RSV）的检测

Poster Presentation

海报展示

Session Title: Diagnostics: Virology

课程名称：诊断学：病毒学

Date: Saturday, October 19, 2024

日期：2024年10月19日，星期六

Time: 12:15 PM –1:30 PM PT

时间：下午12:15–1:30 PT

Location: Halls J & K

地点：J&K大厅

FluMist

喷雾器

Effectiveness of live attenuated and inactivated influenza vaccines in children: data from the 2023/24 influenza season

减毒活疫苗和灭活疫苗对儿童的有效性：2023/24流感季节的数据

Poster Presentation

海报展示

Session Title: Pediatric Vaccines

课程名称：儿科疫苗

Date: Thursday, October 17, 2024

日期：2024年10月17日，星期四

Time: 12:15 PM –1:30 PM PT

时间：下午12:15–1:30 PT

Location: Halls J & K

地点：J&K大厅

Early Science

早期科学

Anti-toxin B neutralizing monoclonal antibody AZD5148 provides protection in a clostridioides difficile gnotobiotic piglet model

抗毒素B中和单克隆抗体AZD5148在艰难梭菌感染仔猪模型中提供保护

Poster Presentation

海报展示

Session Title: New Drug Development

课程名称：新药开发

Date: Friday, October 18, 2024

日期：2024年10月18日，星期五

Time: 12:15 PM - 1:30 PM PT

时间：下午12:15-下午1:30 PT

Location: Halls J & K

地点：J&K大厅

Lower Respiratory Tract Disease Real-World Evidence

下呼吸道疾病的真实世界证据

A need for infection prevention among patients with ESKD on maintenance dialysis: a first step in understanding how SARS-CoV-2 impacts this population

维持性透析的ESKD患者需要预防感染：了解SARS-CoV-2如何影响这一人群的第一步

Poster Presentation

海报展示

Session Title: HAIs: Surveillance

会议标题：Hais：监控

Date: Thursday, October 18, 2024

日期：2024年10月18日，星期四

Time: 12:15 PM – 1:30 PM PT

时间：下午12:15–1:30 PT

Location: Halls J & K

地点：J&K大厅

Global incidence of viral lower respiratory tract disease (LRTD) episodes and hospitalizations (2010-2021)

病毒性下呼吸道疾病（LRTD）发作和住院的全球发病率（2010-2021）

Oral Presentation

口头陈述

Session Title: Navigating Acute Respiratory Infections

课程名称：应对急性呼吸道感染

Date: Friday, October 18, 2024

日期：2024年10月18日，星期五

Time: 10:30 AM – 11:45 AM PT

时间：太平洋时间上午10:30–11:45

Location: 408 A

位置：408 A

Notes

注意事项

FluMist (Live Attenuated Influenza Vaccine)

FluMist（流感减毒活疫苗）

FluMist is a live attenuated influenza vaccine (LAIV) administered as a nasal spray for the prevention of influenza. FluMist is an Advisory Committee on Immunization Practices (ACIP) and American Academy of Pediatrics (AAP) recommended influenza vaccine option. FluMist was originally approved in the US in 2003 and since then almost 200 million doses have been distributed around the world.11 In September 2024, the US FDA approved an expansion to those who can administer FluMist to include self-administration for eligible 18-49 year olds or administration by a caregiver for eligible 2-17 year olds.12 The self/caregiver administration option will be available as soon as the 2025/26 influenza season.13.

FluMist是一种减毒活流感疫苗（LAIV），作为鼻喷雾剂用于预防流感。FluMist是免疫实践咨询委员会（ACIP）和美国儿科学会（AAP）推荐的流感疫苗选择。FluMist最初于2003年在美国获得批准，自那时以来，已经在世界各地分发了近2亿剂.11 2024年9月，美国FDA批准将FluMist的管理范围扩大到那些可以管理FluMist的人，包括符合条件的18-49岁的自我管理或由符合条件的2-17岁的照顾者管理.12自我/照顾者管理选项将在2025/26流感季节尽快提供.13。

IVX-A12

IVX-A12

IVX-A12 is a liquid, refrigerator-stable formulation comprised of IVX-121, Icosavax’s RSV prefusion F protein VLP vaccine candidate, and IVX-241, Icosavax’s hMPV prefusion F protein VLP vaccine candidate.7 IVX-A12 was acquired with AstraZeneca’s acquisition of Icosavax.

IVX-A12是一种液体，冰箱稳定配方，由IVX-121，Icosavax的RSV预融合F蛋白VLP候选疫苗和IVX-241，Icosavax的hMPV预融合F蛋白VLP候选疫苗组成。7 IVX-A12是通过阿斯利康收购Icosavax获得的。

In the Phase II trial, IVX-A12 showed robust immune responses across RSV and hMPV antibodies, reconfirming previous immunogenicity data seen in the smaller Phase I trial.6,7 The data are the first to demonstrate hMPV immune response in a Phase II combination vaccine trial.6,7 IVX-A12 was generally well-tolerated in the trial, with a safety profile similar to that seen in the Phase I trial.6,7.

在II期试验中，IVX-A12在RSV和hMPV抗体中显示出强大的免疫反应，再次证实了之前在较小的I期试验中看到的免疫原性数据[6,7]。这些数据是第一个证明hMPV免疫反应的II期联合疫苗试验[6,7]。IVX-A12在试验中通常耐受性良好，安全性与I期试验相似[6,7]。

IVX-A12 has been granted Fast Track Designation from the US Food and Drug Administration, a programme designed to facilitate the development and expedite the review of investigational drugs to treat serious conditions and fulfill an unmet medical need.14 If approved, IVX-A12 will be the world’s first-in-class, differentiated, combination vaccine targeting RSV and hMPV to prevent lower respiratory tract disease..

IVX-A12已获得美国食品和药物管理局的快速通道指定，该计划旨在促进研究药物的开发和加速审查，以治疗严重疾病并满足未满足的医疗需求.14如果获得批准，IVX-A12将成为世界上第一种针对RSV和hMPV的有区别的组合疫苗，以预防下呼吸道疾病。。

Beyfortus

Beyfortus

Beyfortus (nirsevimab) is a single dose long-acting antibody, developed and commercialised in partnership by AstraZeneca and Sanofi using AstraZeneca’s YTE extended-half-life technology. It is designed to protect infants born during or entering their first RSV season and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Beyfortus（nirsevimab）是一种单剂量长效抗体，由阿斯利康和赛诺菲合作开发并商业化，使用阿斯利康的YTE延长半衰期技术。它旨在保护在第一个RSV季节出生或进入第一个RSV季节的婴儿，以及在第二个RSV季节仍然容易感染严重RSV疾病的24个月大的儿童。

Beyfortus, provided directly to newborns and infants as a single dose, offers rapid protection via an antibody to help prevent LRTD caused by RSV, without requiring activation of the immune system.15.

Beyfortus作为单剂量直接提供给新生儿和婴儿，通过抗体提供快速保护，以帮助预防由RSV引起的LRTD，而无需激活免疫系统。

Beyfortus administration can be timed to the start of the RSV season.15

Beyfortus管理层可以安排在RSV赛季开始时。15

Beyfortus was granted regulatory designations to facilitate expedited development by several major regulatory agencies around the world. Beyfortus has been approved for use in the European Union, China and Japan and received approval by the US Food and Drug Administration following a unanimous recommendation by the Antimicrobial Drugs Advisory Committee. Beyfortus is recommended by the Advisory Committee on Immunization Practices for broad infant use and was included in the Vaccines for Children programme in the US.6 Early data from the US Centers for Disease Control and Prevention, show that in the 2023/4 RSV season, Beyfortus was associated with a 90% reduction against RSV-associated hospitalisation among infants in their first RSV season.16.

Beyfortus被授予监管指定，以促进世界各地几个主要监管机构的快速发展。Beyfortus已被批准在欧盟、中国和日本使用，并在抗菌药物咨询委员会的一致建议下获得美国食品和药物管理局的批准。Beyfortus是免疫实践咨询委员会推荐的广泛用于婴儿的疫苗，并被纳入美国儿童疫苗计划[6]。美国疾病控制和预防中心的早期数据显示，在2023/4年RSV季节，Beyfortus在第一个RSV季节，婴儿RSV相关住院率降低了90%。

IDWeek 2024™

2024国际数字周™

IDWeek 2024TM is an annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS) and the Society of Infectious Diseases Pharmacists (SIDP). With the theme “Advancing Science, Improving Care,” IDWeek features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2024™ takes place 16-19 October at the Los Angeles Convention Center (1201 S Figueroa St) in Los Angeles, CA.

IDWeek 2024TM是美国传染病协会（IDSA）、美国医疗保健流行病学协会（SHEA）、艾滋病毒医学协会（HIVMA）、儿科传染病协会（PIDS）和传染病药剂师协会（SIDP）的年会。IDWeek以“推进科学，改善护理”为主题，介绍了包括艾滋病毒在内的传染病在整个生命周期中的预防，诊断，治疗和流行病学方面的最新科学和从实验室到床边的方法。IDWeek 2024™于10月16日至19日在加利福尼亚州洛杉矶的洛杉矶会议中心（菲格罗街1201号）举行。

For more information, visit www.idweek.org..

有关更多信息，请访问www.idweek.org。。

AstraZeneca

阿斯利康

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

阿斯利康（LSE/STO/Nasdaq:AZN）是一家全球科学领先的生物制药公司，专注于肿瘤学，罕见病和生物制药（包括心血管，肾脏和代谢以及呼吸和免疫学）处方药的发现，开发和商业化。

Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca..

阿斯利康的创新药物总部位于英国剑桥，在125多个国家销售，全球数百万患者使用。请访问astrazeneca.com并在社交媒体@astrazeneca上关注该公司。。

Contacts

联系人

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

有关如何联系投资者关系团队的详细信息，请单击此处。有关媒体联系人，请单击此处。

References

参考文献

U.S. Centers for Disease Control and Prevention. About Human Metapneumovirus. Accessed 7 October 2024. https://www.cdc.gov/human-metapneumovirus/about/

U、 美国疾病控制和预防中心。关于人类偏肺病毒。https://www.cdc.gov/human-metapneumovirus/about/

Billard MN, Wildenbeest JG, Braas O, et al. Global surveillance of human Metapneumovirus (hMPV) and respiratory syncytial virus (RSV) epidemiology since 2022. Presented at: IDWeek 2024; 16-19 October 2024; Los Angeles, California. Abs P-2338

Billard MN，Wildenbeest JG，Braas O等。自2022年以来，人类偏肺病毒（hMPV）和呼吸道合胞病毒（RSV）流行病学的全球监测。提交时间：IDWeek 2024；2024年10月16日至19日；加利福尼亚州洛杉矶。Abs P-2338

Bhaskar N, Abul Y, Devone F, et al. Outcomes of human Metapneumovirus in nursing home residents: a matched analysis. Presented at: IDWeek 2024; 16-19 October 2024; Los Angeles, California. Abs P-342

Bhaskar N，Abul Y，Devone F等人。疗养院居民中人类偏肺病毒的结果：匹配分析。提交时间：IDWeek 2024；2024年10月16日至19日；加利福尼亚州洛杉矶。Abs P-342

Dube S, Carty L, Talarico C. Individuals on Immunosuppressive or Immunomodulatory Therapies Remain at Increased Risk of COVID-19 Hospitalization, Despite Vaccination: Findings from INFORM, a Retrospective Health Database Study in England. Presented at: IDWeek 2024; 16-19 October 2024; Los Angeles, California.

Dube S，Carty L，Talarico C.尽管接种了疫苗，但接受免疫抑制或免疫调节治疗的个体仍有增加的COVID-19住院风险：英国回顾性健康数据库研究INFORM的发现。提交时间：IDWeek 2024；2024年10月16日至19日；加利福尼亚州洛杉矶。

Abs P-2006.

Abs P-2006。

Carty L, Dube S, Talarico C, et al. COVID-19 Mortality Among Immunocompromised Individuals is Consistently High Compared with Non-Immunocompromised Individuals: Results of the INFORM Study 2022, England. Presented at: IDWeek 2024; 16-19 October 2024; Los Angeles, California. Abs P-1989

Carty L，Dube S，Talarico C等人。与非免疫功能低下的个体相比，免疫功能低下个体的新型冠状病毒肺炎死亡率一直很高：英国INFORM 2022研究的结果。提交时间：IDWeek 2024；2024年10月16日至19日；加利福尼亚州洛杉矶。Abs P-1989

Davis M, Shapiro C, Adams M, et al. Safety and immunogenicity of a Respiratory Syncytial Virus and human Metapneumovirus virus-like particle protein subunit combination vaccine in 60–85-year-old adults: interim results from a Phase 2a clinical trial. Presented at: IDWeek 2024; 16-19 October 2024; Los Angeles, California.

Davis M，Shapiro C，Adams M等人。呼吸道合胞病毒和人类偏肺病毒样颗粒蛋白亚基联合疫苗在60-85岁成年人中的安全性和免疫原性：2a期临床试验的中期结果。提交时间：IDWeek 2024；2024年10月16日至19日；加利福尼亚州洛杉矶。

Abs P-601.

Abs P-601。

Icosavax [press release]. Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults. 12 December 2023. Accessed 20 September 2024. https://www.globenewswire.com/en/news-release/2023/12/12/2794421/0/en/Icosavax-Announces-Positive-Topline-Interim-Phase-2-Results-for-Combination-VLP-Vaccine-Candidate-IVX-A12-Against-RSV-and-hMPV-in-Older-Adults.html.

Icosavax[新闻稿]。Icosavax宣布针对老年人RSV和hMPV的VLP候选组合疫苗IVX-A12的阳性Topline中期2期结果。2023年12月12日。https://www.globenewswire.com/en/news-release/2023/12/12/2794421/0/en/Icosavax-Announces-Positive-Topline-Interim-Phase-2-Results-for-Combination-VLP-Vaccine-Candidate-IVX-A12-Against-RSV-and-hMPV-in-Older-Adults.html.

Bandell AR, Barker C, Dibben O. Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children: Data from the 2023/24 Influenza Season. Presented at: IDWeek 2024; 16-19 October 2024; Los Angeles, California. Abs P-612

。提交时间：IDWeek 2024；2024年10月16日至19日；加利福尼亚州洛杉矶。Abs P-612

Tkaczyk C, Dayao D, Girouard D, et al. Anti-Toxin B Neutralizing Monoclonal Antibody AZD5148 Provides Protection in a Clostridioides difficile Gnotobiotic Piglet Model. Presented at: IDWeek 2024; 16-19 October 2024; Los Angeles, California. Abs P-1055

Tkaczyk C，Dayao D，Girouard D等。抗毒素B中和单克隆抗体AZD5148在艰难梭菌非生物仔猪模型中提供保护。提交时间：IDWeek 2024；2024年10月16日至19日；加利福尼亚州洛杉矶。Abs P-1055

Sincero SR, Streicher K, Kelly EJ, e t al. Nirsevimab in Patient Samples Does Not Interfere with Respiratory Syncytial Virus (RSV) Detection by Commercially Available Rapid Antigen Tests. Presented at: IDWeek 2024; 16-19 October 2024; Los Angeles, California. Abs P-2179

患者样品中的Sincero SR，Streicher K，Kelly EJ，e t al。Nirsevimab不干扰通过市售快速抗原测试检测呼吸道合胞病毒（RSV）。提交时间：IDWeek 2024；2024年10月16日至19日；加利福尼亚州洛杉矶。Abs P-2179

FluMist Prescribing Information. March 2024.

FluMist处方信息。2024年3月。

AstraZeneca [Press Release]. FluMist approved for self-administration in the US. 20 September 2024. Accessed 3 October 2024. https://www.astrazeneca.com/media-centre/press-releases/2024/flumist-approved-for-self-administration-in-the-us.html

阿斯利康[新闻稿]。。2024年10月3日访问。https://www.astrazeneca.com/media-centre/press-releases/2024/flumist-approved-for-self-administration-in-the-us.html

U.S. Food & Drug Administration. FluMist. 26 December 2024. Accessed 3 October 2024. https://www.fda.gov/vaccines-blood-biologics/vaccines/flumist

U、 美国食品和药物管理局。喷雾器。2024年12月26日。2024年10月3日访问https://www.fda.gov/vaccines-blood-biologics/vaccines/flumist

Icosavax [press release]. Icosavax Granted FDA Fast Track Designation for IVX-A12. 21 February 2023. Accessed 20 September 2024. https://www.globenewswire.com/en/news-release/2023/02/21/2612100/0/en/Icosavax-Granted-FDA-Fast-Track-Designation-for-IVX-A12.html

Icosavax[新闻稿]。Icosavax授予FDA IVX-A12快速通道指定。2023年2月21日。2024年9月20日访问https://www.globenewswire.com/en/news-release/2023/02/21/2612100/0/en/Icosavax-Granted-FDA-Fast-Track-Designation-for-IVX-A12.html

Jones JM, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices – United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(34):920-925.

Jones JM等人，《使用尼塞维单抗预防婴幼儿呼吸道合胞病毒病：免疫实践咨询委员会的建议——美国，2023年》。MMWR Morb Mortal Wkly Rep.2023；72（34）：920-925。

Moline HL, et al. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024. MMWR Morb Mortal Wkly Rep. 2024;73:209–214..

Moline HL等人，《尼塞维单抗预防首次进入呼吸道合胞病毒季节的婴儿呼吸道合胞病毒相关住院的早期评估-新疫苗监测网络》，2023年10月至2024年2月。MMWR Morb Mortal Wkly Rep.2024；73:209–214。。